Contributor
Aparna Krishnan
Menu
Aparna Krishnan
In this episode, the team discuss UK health technology body NICE not recommending Biogen’s Spinraza for routine use in the NHS; CVS announcing the use of ICER’s cost effectiveness analysis to decide formulary inclusions and Express Scripts is in talks with several pharma companies for exclusive distribution rights to sell their upcoming gene therapies.
Presenter: Max Rex
Contributor: Aparna Krishnan
